Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — ØU Life Science Investor Konference 2026
16 slides from Expres2ion Biotech Holding Ab's conference presentation, Mar 25, 2026
Slide 1: First-in-Class HER2 Immunotherapy
First - in- Class HER2 Immunotherapy Inducing durable control in HER2 - driven cancers ØU - Life Science Investor Konference 25 March 2026 Bent U. Frandsen, CEO Hosted by STO: EXPRS2 ExpreS2ion Biotech Holding AB Org. Nr. 559033 - 3729
Slide 2: ExpreS2ion at a Glance
ExpreS2ion at a Glance Clinical - stage biotech developing immunotherapies and vaccines Lead Asset Platform Strategic Position ExpreS2 protein manufacturing ES2B - C001 HER2 immunotherapy 34% AdaptVac ownership technology Phase I clinical Phase III validated Broad infectious diseases pipeline CRO se
Slide 3: The Unmet Need
The Unmet Need Breast Cancer: The #1 Killer in Women’s Health – key background for lead asset Problem Limitation of current therapies Opportunity for immunotherapy • 2.3 million women diagnosed • Resistance develops • Durable immune control each year 1 – the most common • Limited durability cancer •
Slide 4: Our Technology Platform
Our Technology Platform ExpreS2 is applied in ALL our business – VLP technology exclusively in - licensed for lead asset ES2B - C001 ExpreS2 platform AdaptVac VLP technology • Capabilities Exclusive license for HER2-VLP • Capabilities • >500 proteins expressed • High antigen density • 90% success ra
Slide 5: ES2B-C001: First-in-Class HER2 Immunotherapy
ES2B - C001: First - in- Class HER2 Immunotherapy Active immunotherapy designed to induce durable immune control • Mechanism • Presents entire HER2 extracellular domain HER2 protein (all 4 extra - cellular domains, i.e. • Generates polyclonal immune response polyclonal effect) • Targets multiple HER
Slide 6: ES2B-C001: Preclinical Proof-of-Concept
ES2B - C001: Preclinical Proof - of- Concept Significant in vivo tumour inhibition resulted in 100% survival rate in FVB mice Tumour growth inhibition Tumour - free survival 2.5 • Metastasis prevention 3 )3 ) 2.0 (cm(cm Vaccinated Tumor - free (%) Kaplan - Meier survival curve by log Mean+/±-SEM SEM
Slide 7: ES2B-C001: Phase I Clinical Trial
ES2B - C001: Phase I Clinical Trial Preliminary findings support the program Trial design Early observations • Population: ≤27 advanced HER2 - positive or HER2 - low breast cancer patients (post 2 - 3 lines SoC therapy) 1 • Sites: Three clinical centres in Austria • Treatment: Intramuscular vaccine,
Slide 8: ES2B-C001: Large Market Opportunity
ES2B - C001: Large Market Opportunity HER2 - targeted therapies represent a major oncology market Proven Commercial Value of HER2 Drugs (2024, EUR billion) 1 5,0 4,0 Global market: HER2 - expressing breast cancer 3,0 therapies exceeded €17B globally in 2024 1 2,0 Estimated addressable 1,0 opportunit
Slide 9: ES2B-C001: Development Strategy
ES2B - C001: Development Strategy Goal: Out - license when Phase II delivers proof — or earlier if signals are strong 2025 2026 2027 2028 2029 Phase I: First human data Phase II: Proof of Concept in Breast Cancer • Multiple multi - billion Potential parallel Phase II in Industry Gastric Cancer dolla
Slide 10: Pipeline Overview
Pipeline Overview Multiple shots on goal across cancer and infectious diseases, powered by our ExpreS2 platform, and AdaptVac’s VLP in some cases Target Pre - clinical DISEASE Project/Target ID Identification Pharmacology cGMP / Tox Phase I Phase II Phase III Collaboration Partner Platform 1 100% Br
Slide 11: Rights Issue
Rights Issue Funding to complete Phase I and reach value inflection Cash Development Last 18 Months Important Cash In - flow in 2026 100 Rights Issue of ~53mSEK • ~60% secured 82 • Subscription period: Apr. 16 – 30, ‘26 • Terms: 1 share = 1 unit (1 new share + TO13 warrant) 69 • Price: 70% of the av
Slide 12: Leadership: Fully capable of executing to Phase II
Leadership: Fully capable of executing to Phase II Extensive Clinical Development, Oncology & Licensing Experience + 15 FTE colleagues (6 PhDs) Executive + consulting executives Management Bent U. Frandsen, MSc Keith Alexander, MSc Dr. Max M. Soegaard, PhD 200+ years of clinical development and phar
Slide 13: Upcoming Catalysts
Upcoming Catalysts Multiple value - driving readouts anticipated over the next 12 - 18 months ES2B - C001 Phase Ib expansion Phase Ia dose escalation Outlicensing / (Breast RP2D + safety/immunogenicity Interim safety/immunogenicity readouts Phase II cancer) Preliminary efficacy signals GMP batch rel
Slide 14: Why Invest Now
Why Invest Now 1️⃣ First- in- class HER 2 immunotherapy 2️⃣ Encouraging immune responses in Phase I 3️⃣ Validated protein platform ( Phase III track record ) 4️⃣ €17B HER 2 oncology market 5️⃣ Clear Phase I/II licensing strategy 6️⃣ Multiple catalysts over next 12- 18 months Timing and success of fu
Slide 15: Q&A
Q&A NASDAQ FN: EXPRS2 Innovative immunotherapies for a healthier world investor@ expres2ionbio.com https://investor. expres2ionbio.com
Slide 16: Disclaimer
Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to u nde rwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company”). Neither shall the presentation or any part of
ExpreS2ion Biotech Holding — ØU Life Science Investor Konference 2026 on 6ix